Leerink Swann reiterates an 'Outperform' on Regeneron Pharma (REGN); Eylea Posts an Eye-Popping 1st Quarter of Launch
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $834.04 +0.90%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Leerink Swann reiterates an 'Outperform' on Regeneron Pharma (NASDAQ: REGN) price target range raised to $76-$80.
Leerink analyst says, "We have adjusted our 2012E U.S. Eylea sales to $153m (versus $106m consensus) in light of the new guidance. Our 2013 and 2014 U.S. Eylea sales estimates are $369m and $640m, respectively (versus $260m and $439m consensus)."
"Reimbursement Already Occurring: While the company will not have a permanent J-code until next January, there are some doctors who are already receiving reimbursement for Eylea."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $65.48 yesterday.
Leerink analyst says, "We have adjusted our 2012E U.S. Eylea sales to $153m (versus $106m consensus) in light of the new guidance. Our 2013 and 2014 U.S. Eylea sales estimates are $369m and $640m, respectively (versus $260m and $439m consensus)."
"Reimbursement Already Occurring: While the company will not have a permanent J-code until next January, there are some doctors who are already receiving reimbursement for Eylea."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $65.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
